{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:05:18Z","timestamp":1779285918247,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"publisher","award":["25-12456-BO"],"award-info":[{"award-number":["25-12456-BO"]}],"id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.modpat.2026.100987","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:20:20Z","timestamp":1772558420000},"page":"100987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary Angiosarcomas of the Thyroid: New Insights Into the Genetic Background and Potentially Targetable Therapeutic Markers of an Ultrarare Disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Marc","family":"Ingenwerth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Pretzell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Bednaric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cagla","family":"Basol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Kalbourtzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Brandenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara","family":"Machlah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"F\u00fchrer-Sakel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-6469","authenticated-orcid":false,"given":"Sarah","family":"Theurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.modpat.2026.100987_bib1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/cup.13912","article-title":"MYC gene amplification by fluorescence in situ hybridization and MYC protein expression by immunohistochemistry in the diagnosis of cutaneous angiosarcoma: systematic review and appropriate use criteria","volume":"48","author":"Motaparthi","year":"2021","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.modpat.2026.100987_bib2","volume":"vol 10","year":"2025"},{"key":"10.1016\/j.modpat.2026.100987_bib3","volume":"vol 3","year":"2020"},{"key":"10.1016\/j.modpat.2026.100987_bib4","volume":"vol 12","year":"2025"},{"issue":"1","key":"10.1016\/j.modpat.2026.100987_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.semdp.2025.150979","article-title":"Thyroid angiosarcoma: a comprehensive review","volume":"43","author":"Arcovito","year":"2026","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.modpat.2026.100987_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.oraloncology.2018.05.004","article-title":"Primary thyroid angiosarcoma: a systematic review","volume":"82","author":"De Felice","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.modpat.2026.100987_bib7","series-title":"WHO Classification of Tumours of Endocrine Organs","author":"Lloyd","year":"2017"},{"key":"10.1016\/j.modpat.2026.100987_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156240","article-title":"A subgroup of anaplastic thyroid carcinomas harbors MET alterations with potential therapeutic options","volume":"275","author":"Theurer","year":"2025","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.modpat.2026.100987_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"19","key":"10.1016\/j.modpat.2026.100987_bib10","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.3390\/cancers17193163","article-title":"Novel therapeutic approaches for cutaneous angiosarcoma, particularly focusing on immune checkpoint inhibitors","volume":"17","author":"Fujisawa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.modpat.2026.100987_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00107","article-title":"Dramatic response of a PD-L1-positive advanced angiosarcoma of the scalp to pembrolizumab","volume":"2","author":"Hamacher","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"18","key":"10.1016\/j.modpat.2026.100987_bib12","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1002\/cncr.34370","article-title":"Clinical activity of checkpoint inhibitors in angiosarcoma: a retrospective cohort study","volume":"128","author":"Ravi","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2026.100987_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004149","article-title":"Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center","volume":"10","author":"Rosenbaum","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2026.100987_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12026-021-09259-4","article-title":"Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups","volume":"70","author":"Tomassen","year":"2022","journal-title":"Immunol Res"},{"issue":"10","key":"10.1016\/j.modpat.2026.100987_bib15","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.prp.2018.07.017","article-title":"High expression of TROP2 is correlated with poor prognosis of oral squamous cell carcinoma","volume":"214","author":"Tang","year":"2018","journal-title":"Pathol Res Pract"},{"issue":"2","key":"10.1016\/j.modpat.2026.100987_bib16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11605-012-2105-1","article-title":"TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma","volume":"17","author":"Ning","year":"2013","journal-title":"J Gastrointest Surg"},{"issue":"10411","key":"10.1016\/j.modpat.2026.100987_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.modpat.2026.100987_bib18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.100987_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.modpat.2026.100987_bib20","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1158\/1078-0432.CCR-23-3924","article-title":"Sacituzumab govitecan demonstrates efficacy across tumor trop-2 expression levels in patients with advanced urothelial cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2026.100987_bib21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.modpat.2026.100987_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010212","article-title":"FAP-targeted radioligand therapy with (68)Ga\/(177)Lu-DOTA-2P(FAPI)(2) enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.modpat.2026.100987_bib23","first-page":"1922","article-title":"Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification","volume":"56","author":"Reubi","year":"1996","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2026.100987_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/antib14010026","article-title":"Future landscape of anti-claudin 18.2 antibodies in gastric adenocarcinoma","volume":"14","author":"Covert","year":"2025","journal-title":"Antibodies (Basel)"},{"issue":"1","key":"10.1016\/j.modpat.2026.100987_bib25","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1038\/s41598-022-07727-x","article-title":"Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma","volume":"12","author":"Tanaka","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.modpat.2026.100987_bib26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41379-018-0199-z","article-title":"Angiosarcoma and anaplastic carcinoma of the thyroid are two distinct entities: a morphologic, immunohistochemical, and genetic study","volume":"32","author":"Kuhn","year":"2019","journal-title":"Mod Pathol"},{"issue":"19","key":"10.1016\/j.modpat.2026.100987_bib27","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.3390\/cancers13194816","article-title":"Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis","volume":"13","author":"Espejo-Freire","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.modpat.2026.100987_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/his.14458","article-title":"The genetics of vascular tumours: an update","volume":"80","author":"Torrence","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2026.100987_bib29","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2147\/CMAR.S159641","article-title":"A review of soft-tissue sarcomas: translation of biological advances into treatment measures","volume":"10","author":"Hoang","year":"2018","journal-title":"Cancer Manag Res"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522600030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522600030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:05:07Z","timestamp":1779282307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089339522600030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S089339522600030X"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100987","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Angiosarcomas of the Thyroid: New Insights Into the Genetic Background and Potentially Targetable Therapeutic Markers of an Ultrarare Disease","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100987"}}